Adjust Text Size:
Browse Clinical Trials
Join the Email List
Sign up for our email bulletin
Participant Stories
“I participate because it is the right thing to do, for myself, for my children, and for the millions of people who have Parkinson’s disease. Without participation there will be no cure.” –Mike, Diagnosed 7 years
Recently Diagnosed with Parkinson's Disease?
If you have recently been diagnosed with Parkinson’s disease (PD) understanding the disease, and learning about the resources available to you, are good first steps.
News Archive
Researchers Discover MicroRNA-7, a Possible Therapeutic Target to Slow Parkinson’s Disease
Jul 20 2009
Researchers have discovered a therapeutic target that, when manipulated, may slow the progression of or halt Parkinson’s disease, a debilitating neurodegenerative disorder that affects an estimated one million people in the United States.
A team from the Center for Neurodegenerative and Neuroimmunologic Diseases in the Department of Neurology at the University of Medicine and Dentistry of New Jersey (UMDNJ) -Robert Wood Johnson Medical School carried out the study. M. Maral Mouradian, MD, center director and William Dow Lovett Professor of Neurology, was its lead investigator. A paper on their findings, titled “Repression of a-synuclein expression and toxicity by microRNA-7,” appears in the July 20 edition of the Proceedings of the National Academy of Sciences (PNAS).
In this publication, the investigators report that the small RNA molecule microRNA-7, which is present in neurons, directly represses the expression of alpha-synuclein, a protein that, in excess, proves deleterious to certain types of brain cells.
“Individuals who have multiple copies of the alpha-synuclein gene come down with Parkinson’s, so inhibitors of alpha-synuclein expression are attractive therapeutic targets,” explained Mouradian. “Our manipulation protects neuronal cells from the toxicity that results from increased levels of this protein.”
There is no cure for Parkinson’s and there are no neuroprotective treatments as of yet, making this new strategy to manipulate the molecular underpinnings of the disease a significant discovery, Mouradian added.
